Last reviewed · How we verify
Brivanib 800 mg, QD
Brivanib 800 mg, QD is a Dual FGFR/VEGFR inhibitor Small molecule drug developed by Zai Lab (Shanghai) Co., Ltd.. It is currently in Phase 2 development for Hepatocellular carcinoma, Advanced solid tumors.
Brivanib is a dual inhibitor of fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR) that blocks angiogenesis and tumor cell proliferation.
Brivanib is a dual inhibitor of fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR) that blocks angiogenesis and tumor cell proliferation. Used for Hepatocellular carcinoma, Advanced solid tumors.
At a glance
| Generic name | Brivanib 800 mg, QD |
|---|---|
| Sponsor | Zai Lab (Shanghai) Co., Ltd. |
| Drug class | Dual FGFR/VEGFR inhibitor |
| Target | FGFR, VEGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Brivanib inhibits both FGFR and VEGFR signaling pathways, which are critical for tumor angiogenesis and growth. By blocking these receptor tyrosine kinases, the drug reduces new blood vessel formation to tumors and directly inhibits cancer cell proliferation. This dual-target approach aims to overcome resistance mechanisms that may develop with single-pathway inhibition.
Approved indications
- Hepatocellular carcinoma
- Advanced solid tumors
Common side effects
- Diarrhea
- Fatigue
- Nausea
- Hypertension
- Abdominal pain
Key clinical trials
- MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients (PHASE1, PHASE2)
- Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer (PHASE3)
- A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC (PHASE2)
- Phase I/II Combination With Irinotecan- Erbitux (PHASE1, PHASE2)
- A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664) (PHASE1)
- BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies (PHASE1)
- A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Brivanib 800 mg, QD CI brief — competitive landscape report
- Brivanib 800 mg, QD updates RSS · CI watch RSS
- Zai Lab (Shanghai) Co., Ltd. portfolio CI
Frequently asked questions about Brivanib 800 mg, QD
What is Brivanib 800 mg, QD?
How does Brivanib 800 mg, QD work?
What is Brivanib 800 mg, QD used for?
Who makes Brivanib 800 mg, QD?
What drug class is Brivanib 800 mg, QD in?
What development phase is Brivanib 800 mg, QD in?
What are the side effects of Brivanib 800 mg, QD?
What does Brivanib 800 mg, QD target?
Related
- Drug class: All Dual FGFR/VEGFR inhibitor drugs
- Target: All drugs targeting FGFR, VEGFR
- Manufacturer: Zai Lab (Shanghai) Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Hepatocellular carcinoma
- Indication: Drugs for Advanced solid tumors
- Compare: Brivanib 800 mg, QD vs similar drugs
- Pricing: Brivanib 800 mg, QD cost, discount & access